Literature DB >> 10971596

Problems associated with switch to modafinil - a novel alerting agent in narcolepsy.

C Guilleminault1, F A Aftab, D Karadeniz, P Philip, D Leger.   

Abstract

Modafinil is a novel medication recently approved for the treatment of narcolepsy and idiopathic hypersomnia. Commonly, patients had already been prescribed medications for their syndrome. This report outlines difficulties encountered in the clinical practice of switching patients to modafinil. Naïve subjects accepted modafinil best. Subjects withdrawn from amphetamine had the most problems and failure to withdraw. Venlafaxine hydrochloride combined well with modafinil to control cataplectic attacks. Usage of a progressive withdrawal protocol may ease the difficulties observed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10971596     DOI: 10.1046/j.1468-1331.2000.00087.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  4 in total

1.  Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies.

Authors:  Michael J Thorpy; Jonathan R L Schwartz; Ruzica Kovacevic-Ristanovic; Roza Hayduk
Journal:  Psychopharmacology (Berl)       Date:  2003-04-23       Impact factor: 4.530

Review 2.  Benefits and risks of pharmacotherapy for narcolepsy.

Authors:  Merrill M Mitler; Roza Hayduk
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Treatment of narcolepsy and other hypersomnias of central origin.

Authors:  Merrill S Wise; Donna L Arand; R Robert Auger; Stephen N Brooks; Nathaniel F Watson
Journal:  Sleep       Date:  2007-12       Impact factor: 5.849

Review 4.  Unmet needs of patients with narcolepsy: perspectives on emerging treatment options.

Authors:  Dariusz R Wozniak; Timothy G Quinnell
Journal:  Nat Sci Sleep       Date:  2015-05-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.